%0 Journal Article
%T Obinutuzumab activates Fc¦ÃRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
%A Noah Kaynan
%A Ofer Mandelboim
%A Rebecca Kotzur
%A Shira Kahlon
%A Shlomo Elias
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2018.1428158
%K anti-CD20
%K CLL
%K Fc receptors
%K obinutuzumab
%K rituximab
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980409/